Navigation Links
New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
Date:9/18/2007

Reinforces Importance of DHA/ARA in Infant Diet

EVANSVILLE, Ind., Sept. 18 /PRNewswire-FirstCall/ -- A recently published study of 4 year olds who had been fed Enfamil LIPIL infant formula exclusively for their first 17 weeks of life has become the longest-term analysis of its kind to demonstrate breastfed-equivalent visual and IQ outcomes among formula- fed infants.(1) The study, which appeared in the journal Early Human Development, was funded by a grant from the National Institutes of Health.

"What this study means for parents is that we now have even longer-term evidence that DHA and ARA supplementation at the levels in Enfamil LIPIL is associated with visual acuity and brain development benefits similar to breast milk," said Deborah Diersen-Schade, Ph.D., a research fellow at Mead Johnson Nutritionals. Previously, brain and eye development outcomes similar to breast milk had been followed in the same group of infants out to 18 months of age.(2, 3)

DHA (docosahexaenoic acid) and ARA (arachidonic acid) are nutrients known as "long-chain polyunsaturated fatty acids (LCPUFA)" that are present in breast milk.

They are critical for development of the eyes, brain and central nervous system. They begin accumulating in the infant's tissues during gestation, especially during the third trimester. Recent evidence suggests that they continue to support the development of visual acuity throughout the first full year of life.(4)

Dr. Diersen-Schade emphasized that the new study addresses two other issues that are important for parents and physicians -- those issues being DHA and ARA levels and control group outcomes.

"The levels of DHA and ARA in Enfamil LIPIL were derived from our evaluation of the levels of both nutrients in human milk worldwide," she said. "The results that Dr. Birch and her colleagues obtained from this analysis as well as earlier positive results from previous studies are based on formulas with DHA at those levels. Researchers who have conducted studies of infant formula that included lower levels have not consistently demonstrated improved outcomes when compared with formula not containing DHA and ARA." (5,6)

Regarding control group outcomes, Diersen-Schade explained that the recent Birch study, which enrolled infants born from 1993 to 1995, also included a control group of infants who received Enfamil with Iron as it was available at the time without DHA and ARA supplementation.

"There were significant differences in visual acuity and verbal IQ scores in the control group versus the breastfed group," she said. "That's important; but what's meaningful is that the similar outcomes for Enfamil LIPIL compared to breast milk were still observable at 4 years of age. Equally interesting, the DHA and ARA group was fed Enfamil LIPIL for only four months; yet their results were similar to infants who were breastfed on average for 10 months."

John Colombo, Ph.D., associate director for cognitive neuroscience and professor of psychology at the University of Kansas, said that the Birch study provides long-awaited data about the links between fatty acids in the infant diet and measures of cognitive function, such as IQ. "Quite simply, these data are the clearest evidence yet that show the beneficial effects of LCPUFA on cognitive and intellectual development - and that LCPUFA should be part of the nutritional regimen in early life," he said. "These results suggest that formulas supplemented with these levels of LCPUFA produce gains in cognitive and intellectual function over formulas without these levels."

About Mead Johnson

Mead Johnson Nutritionals is a world leader in nutrition, dedicated to helping provide infants and children with the best start in life. Mead Johnson Nutritionals is a Bristol-Myers Squibb company.

References

1. Birch EE et al. Visual acuity and cognitive outcomes at 4 years of age

in a double-blind, randomized trial of long-chain polyunsaturated

fatty-acid supplemented infant formula. Early Hum Dev (2007), doi:

10.1016/j.earlhumdev.2006.11.003

2. Birch EE et al. A randomized controlled trial of early dietary supply

of long-chain polyunsaturated fatty acids and mental development in

term infants. Dev Med Child Neurol (2000); 42:174-81.

3. Hoffman DR, et al. Maturation of visual and mental function in 18-month

old infants receiving dietary long-chain polyunsaturated fatty acids.

FASEB J (2003); 17: A727-A728.

4. Morale SE et al. Duration of long-chain polyunsaturated fatty acids

availability in the diet and visual acuity. Early Hum Dev (2005); 81,

197-203.

5. Auestad N et al. Visual, cognitive, and language assessments at 39

months: a follow-up study of children fed formulas containing

long-chain polyunsaturated fatty acids to 1 year of age. Pediatrics

(2003); 112: 177-83

6. Scott DT. Formula supplementation with long-chain polyunsaturated fatty

acids: are there developmental benefits? Pediatrics (1998); 102: 59.

(Electronic publication.)


'/>"/>
SOURCE Mead Johnson
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... On Thursday, February 16, 2017, ... at the closing bell, while the Dow Jones Industrial ... Moreover, five out of nine sectors ended Thursday,s trading ... sentiment, Stock-Callers.com assessed the following Medical Appliances & Equipment ... SNN ), ABIOMED Inc. (NASDAQ: ABMD ...
(Date:2/16/2017)... 16, 2017 DaVita Inc. (NYSE: DVA ... December 31, 2016. Net income attributable to ... 2016 was $158 million, or $0.80 per share and $880 ... net income attributable to DaVita Inc. for the quarter and ... below, was $192 million, or $0.98 per share, and $789 ...
(Date:2/16/2017)...  Express Scripts (NASDAQ: ESRX ) was recognized today ... within the Health Care: Pharmacy and Other Services category. ... Most Admired Companies," said Tim Wentworth , CEO and President, ... of our 26,000 employees to make medicine more affordable and accessible ... ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each ... goals for each and every seminar, session and class she offers. ... different brainwave tools which help energize creativity, focus mental functions, enhance athletic focus ...
(Date:2/17/2017)... ... 2017 , ... Qualis Health, one of the nation's leading ... DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that are ... award categories, highlighting four of the organization’s current programs:, , ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... fall 2017 season , Trinity Health and the U.S. Soccer Foundation announced today ... program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... – 22 in San Francisco. As part of the Tri-Conference expo, which is ... solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , ...
Breaking Medicine News(10 mins):